Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Fujian Medical University Union Hospital is the lead sponsor of 41 current clinical trials in our China register. 26 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Tislelizumab, Cisplatin and Adebrelimab. The most-studied condition is Esophageal Squamous Cell Carcinoma.

ClinicalTrials.gov trials by status

Recruiting2663%
Not yet open922%
Active, closed512%
By invitation12%

Trials by phase

Not applicable1127%
Observational1024%
Phase 2820%
Phase 3820%
Phase 425%
Phase 1/212%
Phase 112%

Clinical trials sponsored by Fujian Medical University Union Hospital

41 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum NCT06791070 · ClinicalTrials.gov ↗ · Paget Disease, Extramammary, Scrotum Disease Drugs: Disitamab Vedotin, Toripalimab	Phase 2	Recruiting	2025-01	China
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC NCT07296705 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer (MIBC) Drugs: Cisplatin, Gemcitabine, Nab-paclitaxel	Phase 2	Recruiting	2025-10	China
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers Drug: Adebrelimab	Phase 2	Recruiting	2024-04	China
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia. NCT07086391 · ClinicalTrials.gov ↗ · Carbapenem-Resistant Enterobacteriaceae Infection, Pneumonia - Bacterial	Observational	Recruiting	2023-02	China
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Cisplatin, Paclitaxel, Serplulimab	Phase 2	Recruiting	2024-07	China
Tumor Regression Grade As Predictor of Adjuvant Therapy NCT06710665 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Observational	Recruiting	2024-10	China
Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer NCT03466424 · ClinicalTrials.gov ↗ · Radiation Oncology, Rectal Cancer	Observational	Recruiting	2022-08	China
Haplo-Cord HSCT for AML/MDS NCT07588360 · ClinicalTrials.gov ↗ · MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)	Not applicable	Recruiting	2025-10	China
Personalized Optimization of Systematic Prostate Biopsy NCT05998278 · ClinicalTrials.gov ↗ · Prostate Adenocarcinoma	Not applicable	Recruiting	2023-08	China
Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma NCT04009265 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	2019-08	China
Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy NCT07551037 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy	Phase 1	Recruiting	2024-09	China
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy NCT06559696 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	2024-07	China
Leptin: A Marker for AML Chemo-Sensitivity NCT07163728 · ClinicalTrials.gov ↗ · AML, Adult	Observational	Recruiting	2025-08	China
Tubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer NCT07024433 · ClinicalTrials.gov ↗ · Lung Cancer Patients	Not applicable	Recruiting	2025-05	China
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity NCT07587944 · ClinicalTrials.gov ↗ · AML, Adult	Observational	Recruiting	2025-12	China
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). NCT07561892 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Newly Diagnosed, Chemotherapy Effect	Phase 4	Recruiting	2022-04	China
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer NCT05292742 · ClinicalTrials.gov ↗ · Breast Cancer, Adjuvant Therapy Drugs: Capecitabine, Pertuzumab/Trastuzumab, Pyrotinib	Phase 2	Recruiting	2021-07	China
A Registered Cohort Study on Neurodegenerative Associated With Sleep Disorder. NCT05524922 · ClinicalTrials.gov ↗ · Neurodegenerative Disorder	Observational	Recruiting	2021-09	China
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients NCT05704166 · ClinicalTrials.gov ↗ · Acute Lung Injury, Prevention	Phase 2	Recruiting	2023-03	China
A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease NCT06881420 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis	Observational	Recruiting	2024-01	China
A Registered Cohort Study on α-Synucleinopathy NCT05527067 · ClinicalTrials.gov ↗ · α-synucleinopathy	Observational	Recruiting	2021-09	China
Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease NCT07324161 · ClinicalTrials.gov ↗ · Alzheimer s Disease	Not applicable	Recruiting	2025-04	China
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer NCT06441110 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active Drugs: Bacillus Calmette-Guerin, Tislelizumab	Phase 3	Recruiting	2023-06	China
Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application NCT07679256 · ClinicalTrials.gov ↗ · PARKINSON DISEASE (Disorder)	Observational	Recruiting	2024-01	China
Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds NCT05984628 · ClinicalTrials.gov ↗ · Skin Wound, Scar, Hypertrophic	Not applicable	Recruiting	2021-10	China
Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy NCT03734952 · ClinicalTrials.gov ↗ · Radiation Oncology	Not applicable	Recruiting	2023-05	China
A Multimodal Convergent Cohort of Parkinson's Disease at FJMUUH (FJMUUH-PD): Natural History Study NCT07588763 · ClinicalTrials.gov ↗ · Parkinson Disease (PD)	Observational	Not yet open	2026-04	China
Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection NCT07672496 · ClinicalTrials.gov ↗ · Complicated Intra-abdominal Infection (cIAI), Systemic Inflammatory Response, Sepsis Drug: Ulinastatin	Not applicable	Not yet open	2026-10	China
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer NCT07788001 · ClinicalTrials.gov ↗ · Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy	Phase 3	Not yet open	2026-10	China
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy NCT07406815 · ClinicalTrials.gov ↗ · Esophageal Cancer, Recurrent Laryngeal Nerve, ICG (Indocyanine Green)	Phase 3	Not yet open	2026-06	China
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study NCT06785584 · ClinicalTrials.gov ↗ · ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC), MPR Drug: Ensartinib	Phase 4	Not yet open	2025-02	China
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. NCT06630871 · ClinicalTrials.gov ↗ · NMIBC Drug: Tislelizumab	Phase 2	Not yet open	2024-10	China
The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy NCT07303231 · ClinicalTrials.gov ↗ · Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy	Phase 3	Not yet open	2026-01	China
Rezvilutamide for High-Risk Prostate Cancer After Surgery NCT07444983 · ClinicalTrials.gov ↗ · Prostate Cancer (Adenocarcinoma)	Not applicable	Not yet open	2026-02	China
Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST NCT05970900 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumor of Rectum Drug: Imatinib	Phase 3	Not yet open	2023-10	China
Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC NCT06816966 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	By invitation	2023-12	China
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca NCT07493070 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Not applicable	Active, closed	2026-02	China
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. NCT05176002 · ClinicalTrials.gov ↗ · Esophageal Neoplasm, Immunotherapy, Radiotherapy Drug: Camrelizumab	Phase 1/2	Active, closed	2021-11	China
Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study NCT07032220 · ClinicalTrials.gov ↗ · Breast Cancer Surgery, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy (SLNB)	Not applicable	Active, closed	2024-12	China
Effect of Preoperative Individualized Education on Anxiety and Recovery. NCT06419088 · ClinicalTrials.gov ↗ · Education	Not applicable	Active, closed	2024-05	China
PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL NCT07541755 · ClinicalTrials.gov ↗ · Acute T Lymphoblastic Leukemia (T-ALL)	Phase 3	Active, closed	2025-05	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Fujian Medical University Union Hospital trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Tislelizumab3 Cisplatin2 Adebrelimab1 Bacillus Calmette-Guerin1 Camrelizumab1 Capecitabine1 Disitamab Vedotin1 Ensartinib1 Gemcitabine1 Imatinib1 Nab-paclitaxel1 Paclitaxel1 Pertuzumab/Trastuzumab1 Pyrotinib1 Serplulimab1 Toripalimab1 Trastuzumab1 Ulinastatin1 Zanidatamab1

Conditions in Fujian Medical University Union Hospital trials

66 conditions

Esophageal Squamous Cell Carcinoma3 Esophageal Cancer3 Immunotherapy2Radiation Oncology2Acute Myeloid Leukemia2 Breast Cancer2Sentinel Lymph Node2Lymphadenectomy2AML2 Adult2 Neoadjuvant Therapy2Paget Disease, Extramammary1Scrotum Disease1Muscle Invasive Bladder Cancer (MIBC)1Biomarkers1Parkinson Disease (PD)1 Hepatocellular Carcinoma (HCC)1Carbapenem-Resistant Enterobacteriaceae Infection1Pneumonia - Bacterial1Esophageal Squamous Cell Carcinoma (ESCC)1Esophageal Neoplasm1Radiotherapy1 Rectal Cancer1MDS (Myelodysplastic Syndrome)1

By trial register

Register	Trials	Recruiting
Clinical trials in China	41	26

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Esophageal Squamous Cell Carcinoma

Sponsor	Trials
Peking University	5
Hebei Medical University Fourth Hospital	4
Tang-Du Hospital	4
Shanghai Zhongshan Hospital	4
Anhui Provincial Hospital	4
Zhejiang Cancer Hospital	3
Sichuan Cancer Hospital and Research Institute	2
Karolinska University Hospital	1
Shandong Boan Biotechnology	1
Affiliated Cancer Hospital of Shantou University Medical College	1

Sponsors with the most current trials registered for this condition.

Questions about Fujian Medical University Union Hospital trials

How many clinical trials does Fujian Medical University Union Hospital sponsor?

Fujian Medical University Union Hospital is the lead sponsor of 41 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Fujian Medical University Union Hospital trials recruiting?

Yes. 26 of its 41 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fujian Medical University Union Hospital testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Tislelizumab (3), Cisplatin (2), Adebrelimab (1), Bacillus Calmette-Guerin (1) and Camrelizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Fujian Medical University Union Hospital clinical trials